Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors
- 24 September 2018
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 39 (2) , 631-664
Abstract
The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate‐competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.Keywords
Funding Information
- Korea Institute of Science and Technology (E26900)
This publication has 120 references indexed in Scilit:
- Astrocytic regulation of glutamate homeostasis in epilepsyGlia, 2012
- TOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf and DAF-16/FoxOCell Metabolism, 2012
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2Nature Immunology, 2011
- AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1Nature Cell Biology, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent MannerCell Metabolism, 2010
- mTOR regulation of autophagyFEBS Letters, 2010
- Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogasterCell Metabolism, 2010
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006